Profile of:
Elien Mahler
Elien Mahler, MD, PhD, is working as a rheumatologist (2010) and epidemiologist at the Sint Maartenskliniek Nijmegen, The Netherlands. She graduated from the Radboud University in Nijmegen, the Netherlands (medical 1998- 2003, rheumatology trainee 2004-2010) and in addition to her medical degree, she has also obtained a master of science in biomedical sciences and is registered as an epidemiologist (educator prof. dr A. Verbeek). She obtained her PhD in 2018 in Utrecht, the Netherlands on the topic “Contribution to the management of osteoarthritis” (prof.dr. H. Bijlsma, prof.dr. van den Hoogen). Her main clinical interests are spondyloarthritis, psoriatic arthritis and osteoarthritis, which extend to her research interests. She is also a member of the working group spondyloarthritis of the Dutch Society for Rheumatology and a member of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and has co-authored over 20 scientific publications. During the masters, she completed several internships abroad (Cancer Epidemiology Research Unit, Sydney, Australia; University Hospital in Istanbul, Turkey; Holyfamily Hospital Techiman, Ghana). During her studies and residency, she was active in several committees at the Faculty of Medicine and nationally at the Dutch society for rheumatology. Since 2016 Elien Mahler is the clinical educator of the rheumatology training program in the Sint Maartenskliniek.
Full name: Elien Mahler
Current country: Netherlands
Membership level: Associate
Type of membership: Member
Number of publications: 5
One-year effectiveness of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations. (2024)
https://pubmed.ncbi.nlm.nih.gov/38851879/
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial (2022)
https://pubmed.ncbi.nlm.nih.gov/35701155/
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. (2020)
https://pubmed.ncbi.nlm.nih.gov/31941544/
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA) (2020)
https://pubmed.ncbi.nlm.nih.gov/32041657/
Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible? (2019)
https://pubmed.ncbi.nlm.nih.gov/31230083/